Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Smith & Nephew (LSE:SN, ... technology business, today announced its entry into the ... Lesser Toe Repair System. Comprised of three separate ... metatarsophalangeal (MTP) ligament repair and reconstruction, a metatarsal ... proximal Inter-phalanges (PIP) fusion, also known as hammer ...
(Date:7/31/2014)... 31, 2014 The global market for ... by 2020, according to a new study by Grand ... theranostics, and the subsequent introduction of advanced cancer diagnostic ... growth over the next six years. Moreover, the growing ... as cancer, coupled with disease triggering lifestyle habits such ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2014 on Wednesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2014 ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... Inc. (Nasdaq:,NUVA), a medical device company focused on developing ... today,details relating to its fourth quarter and full year ... 19, 2008, after,the close of the market., NuVasive ... 2008 at,5:30 p.m. ET / 2:30 p.m. PT to ...
... of Directors of US,Oncology Holdings, Inc. and its wholly ... "Company") announced that, effective,February 1, 2008, Dale Ross will ... and will continue as the Executive Chairman of the,Company. ... Company,s,President and CEO. The CEO transition is a planned ...
... investors to state, TOPEKA, Kan., Jan. 25 ... a "Come Home to Kansas" initiative that,focuses on ... Kansas. Partners in this project include the Kansas,Department ... Organization and the KTEC PIPELINE., This initiative ...
Cached Biology Technology:NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3US Oncology Announces Realignment of Executive Team 2US Oncology Announces Realignment of Executive Team 3'Come Home to Kansas' Announced by KTEC 2
(Date:7/31/2014)... A first-of-its-kind study of bigeye tuna movements in the ... the Large Pelagics Research Center at the University of ... cover a wide geographical range with pronounced north-south movements ... favor a high-use area off Cape Hatteras southwest of ... a new approach to study one of the most ...
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
(Date:7/31/2014)... has long been known that biomass burning ... as a ritual , slash-and-burn agriculture and wildfires ... health. , But until the release of a ... Engineering Professor Mark Z. Jacobson, the degree of ... Jacobson,s research, detailed in a paper published July ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
... headed by Prof. Johanna Ivaska (University of Turku and VTT ... of Turku and the National Institute for Health and Welfare) ... Published in a leading journal, the study concludes ... and of lung and prostate cancer cells. It is likely ...
... scientists have developed a new, integrated, ten-year science plan to ... role in it. Understanding the carbon cycle is central for ... builds on the first such plan, published in 1999, but ... as agents and managers of carbon cycling and climate change, ...
... COPENHAGEN (16 November 2011) In the lead up ... this month, an independent global commission of eminent scientists today ... how to achieve food security in the face of climate ... commissioners urged immediate, coordinated action toward transforming the food system ...
Cached Biology News:Scientists tackle the carbon conundrum 2Global commission charts pathway for achieving food security in face of climate change 2Global commission charts pathway for achieving food security in face of climate change 3Global commission charts pathway for achieving food security in face of climate change 4Global commission charts pathway for achieving food security in face of climate change 5Global commission charts pathway for achieving food security in face of climate change 6Global commission charts pathway for achieving food security in face of climate change 7
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: